Evidence map›Paper›PMID 34745088›Full record

ArticleFrontiers in immunology2021

Roles of RAGE/ROCK1 Pathway in HMGB1-Induced Early Changes in Barrier Permeability of Human Pulmonary Microvascular Endothelial Cell.

Meng-Jiao Zhao, Hao-Ran Jiang, Jing-Wen Sun, Zi-Ang Wang, Bo Hu, Cheng-Rui Zhu, Xiao-Han Yin, Ming-Ming Chen, Xiao-Chun Ma, Wei-Dong Zhao and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The role of HMGB1 in vascular endothelial cells.Apoptosis : an international journal on programmed cell death · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Meng-Jiao ZhaoDepartment of Critical Care Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.
Hao-Ran JiangDepartment of Breast Oncology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Jing-Wen SunDepartment of Developmental Cell Biology, Key Laboratory of Cell Biology, Ministry of Public Health, and Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang, China.
Zi-Ang WangDepartment of Critical Care Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.
Bo HuDepartment of Critical Care Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.
Cheng-Rui ZhuDepartment of Critical Care Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.
Xiao-Han YinDepartment of Critical Care Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.
Ming-Ming ChenDepartment of Critical Care Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.
Xiao-Chun MaDepartment of Critical Care Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.
Wei-Dong ZhaoDepartment of Developmental Cell Biology, Key Laboratory of Cell Biology, Ministry of Public Health, and Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang, China.
Zheng-Gang LuanDepartment of Critical Care Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: High mobility group box 1 (HMGB1) causes microvascular endothelial cell barrier dysfunction during acute lung injury (ALI) in sepsis, but the mechanisms have not been well understood. We studied the roles of RAGE and Rho kinase 1 (ROCK1) in HMGB1-induced human pulmonary endothelial barrier disruption. Methods: In the present study, the recombinant human high mobility group box 1 (rhHMGB1) was used to stimulate human pulmonary microvascular endothelial cells (HPMECs). The endothelial cell (EC) barrier permeability was examined by detecting FITC-dextran flux. CCK-8 assay was used to detect cell viability under rhHMGB1 treatments. The expression of related molecules involved in RhoA/ROCK1 pathway, phosphorylation of myosin light chain (MLC), F-actin, VE-cadherin and ZO-1 of different treated groups were measured by pull-down assay, western blot and immunofluorescence. Furthermore, we studied the effects of Rho kinase inhibitor (Y-27632), ROCK1/2 siRNA, RAGE-specific blocker (FPS-ZM1) and RAGE siRNA on endothelial barrier properties to elucidate the related mechanisms. Results: In the present study, we demonstrated that rhHMGB1 induced EC barrier hyperpermeability in a dose-dependent and time-dependent manner by measuring FITC-dextran flux, a reflection of the loss of EC barrier integrity. Moreover, rhHMGB1 induced a dose-dependent and time-dependent increases in paracellular gap formation accompanied by the development of stress fiber rearrangement and disruption of VE-cadherin and ZO-1, a phenotypic change related to increased endothelial contractility and endothelial barrier permeability. Using inhibitors and siRNAs directed against RAGE and ROCK1/2, we systematically determined that RAGE mediated the rhHMGB1-induced stress fiber reorganization Conclusion: HMGB1 is capable of disrupting the endothelial barrier integrity. This study demonstrates that HMGB1 activates RhoA/ROCK1 pathway

Indexed as

Capillary PermeabilityCells, CulturedEndothelial CellsHMGB1 ProteinHumansMyosin Light ChainsReceptor for Advanced Glycation End Productsrho-Associated KinasesSignal TransductionHMGB1 ProteinHMGB1 protein, humanMyosin Light ChainsReceptor for Advanced Glycation End Productsrho-Associated KinasesROCK1 protein, humanbarrier permeabilityendotheliumhigh mobility group box 1inflammationsignaling

Identifiers

PMID34745088
PMCPMC8564108
OpenAlexW3207107637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.